Kura Oncology to Report Second Quarter 2019 Financial Results
July 25 2019 - 6:30AM
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage
biopharmaceutical company focused on the development of precision
medicines for the treatment of cancer, today announced that it will
report second quarter 2019 financial results after the close of
U.S. financial markets on Thursday, August 1, 2019. Kura’s
management will host a webcast and conference call at 4:30 p.m. ET
/ 1:30 p.m. PT that day to discuss the financial results and
provide a corporate update.
The live call may be accessed by dialing 877-516-3514 for
domestic callers and 281-973-6129 for international callers and
entering the conference code: 5261899. A live webcast and archive
of the call will be available online from the investor relations
section of the company website at
www.kuraoncology.com.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company
committed to realizing the promise of precision medicines for the
treatment of cancer. The Company’s pipeline consists of small
molecule drug candidates that target cancer signaling pathways
where there is a strong scientific and clinical rationale to
improve outcomes by identifying those patients most likely to
benefit from treatment. Kura’s lead drug candidate is tipifarnib, a
farnesyl transferase inhibitor, for which the Company is conducting
a registration-directed trial of tipifarnib in recurrent or
metastatic patients with HRAS mutant HNSCC. In addition, tipifarnib
is being evaluated in multiple other Phase 2 clinical trials in
solid tumor and hematologic indications. Kura’s pipeline also
includes KO-947, an ERK inhibitor, and KO-539, a menin-MLL
inhibitor. For additional information about Kura, please visit the
Company’s website at www.kuraoncology.com.
Contacts
Company:Pete De SpainVice President, Investor Relations
&Corporate Communications(858)
500-8803pete@kuraoncology.com
Investors:Robert H. UhlManaging DirectorWestwicke Partners,
LLC(858) 356-5932robert.uhl@westwicke.com
Media:Jason SparkManaging DirectorCanale Communications(619)
849-6005jason@canalecomm.com
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Apr 2023 to Apr 2024